Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PRPS1 | P60891 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15581684 | 0.80 | CYP2C19 (0.49) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15581686 | 0.74 | KDM4E (0.57) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL7447521 | 0.74 | KDM4E (0.56) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL7447515 | 0.74 | KDM4E (0.56) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL9229833 | 0.72 | CYP2D6 (0.68) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1408641 | 0.72 | CYP2D6 (0.68) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1408642 | 0.72 | CYP2D6 (0.68) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10327031 | 0.70 | CYP2D6 (0.59) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL6441061 | 0.70 | CYP2D6 (0.59) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326303 | 0.70 | CYP2D6 (0.59) | KDM4ENPC1CYP1A2CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956182-B2 | Process for preparing optically active alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | KDM4E 201/4885NPC1 3609/4885CYP1A2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.